Gene Therapy for Murine Lung Cancer Using an Adenoviral Vector Expressing Interleukin-15

Kurume Medical Journal

Volumn 51, Issue 42433, 2004, Pages 225-233

  Yoshimuta, Taro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

gene therapy; IL 15; innate immunity; lung cancer; NK cells

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 15;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; FEMALE; GENE; GENE EXPRESSION; GENE THERAPY; INNATE IMMUNITY; LACZ GENE; LEWIS CARCINOMA; LUNG CANCER; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MOUSE; MOUSE STRAIN C57BL 6 CR; NATURAL KILLER CELL; NONHUMAN; SPLEEN CELL; TUMOR GROWTH;

ADENOVIRIDAE; ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; INTERFERON TYPE II; INTERLEUKIN-15; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL;

EID: 13444257776     PISSN: 00235679     EISSN: 18812090     Source Type: Journal    
DOI: 10.2739/kurumemedj.51.225     Document Type: Article

References (29)

1. Suzuki K., Nakazato H., Matsui H., Hasumi M., Shibata Y. et al. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol 2001; 69:531-537.
2. Whiteside T.L., Vujanovic N.L., and Herberman R.B. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230:221-244.
3. Carson W.E., Giri J.G., Lindemann M.J., Linett M.L., Ahdieh M. et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180:1395-1403.
4. Fehniger T.A., Shah M.H., Turner M.J., VanDeusen J.B., Whitman S.P. et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999; 162:4511-4520.
5. Huang H., Chen S.H., Kosai K., Finegold M.J., and Woo S.L. Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther 1996; 3:980-987.
6. Caruso M., Pham-Nguyen K., Kwong Y.L., Xu B., Kosai K.I. et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996; 93:11302-11306.
7. Chen S.H., Chen X.H., Wang Y., Kosai K., Finegold M.J. et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995;92:2577-2581.
8. Chen S.H., Kosai K., Xu B., Pham-Nguyen K., Contant C. et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56:3758-3762.
9. O'Malley B.W. Jr., Sewell D.A., Li D., Kosai K., Chen S.H. et al. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol 1997; 11:667-673.
10. Fukunaga M., Takamori S., Hayashi A., Shirouzu K., and Kosai K. Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model. Ann Thorac Surg 2002; 73:1740-1746.
11. Nishimura H., Washizu J., Nakamura N., Enomoto A., and Yoshikai Y. Translational efficiency is up-regulated by alternative exon in murine IL-15 mRNA. J Immunol 1998; 160:936-942.
12. Mizuguchi H., and Kay M.A. A simple method for constructing El- and El/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999; 10:2013-2017.
13. Di Carlo E., Meazza R., Basso S., Rosso O., Comes A. et al. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice. J Pathol 2000; 191:193-201.
14. Balasubramanian S., Chernov-Rogan T., Davis A.M., Whitehorn E., Tate E. et al. Ligand binding kinetics of IL-2 and IL-15 to heteromers formed by extracellular domains of the three IL-2 receptor subunits. Int Immunol 1995;7:1839-1849.
15. Ye W., Zheng L.M., Young J.D., and Liu C.C. The involvement of interleukin (IL)-15 in regulating the differentiation of granulated metrial gland cells in mouse pregnant uterus. J Exp Med 1996; 184:2405-2410.
16. Rosmaraki E.E., Douagi I., Roth C., Colucci F., Cumano A. et al. Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol 2001; 31:1900-1909.
17. Horvath-Arcidiacono J.A., and Bloom E.T. Characterization of human killer cell reactivity against porcine target cells: differential modulation by cytokines. Xenotransplantation 2001; 8:62-74.
18. Yang G., Wang Z.Y., Kim S., Liao J., Seril D.N. et al. Characterization of early pulmonary hyperproliferation and tumor progression and their inhibition by black tea in a 4-(methylnitrosamino)-1 -(3-pyridyl)-1-butanone-induced lung tumorigenesis model with A/J mice. Cancer Res 1997; 57:1889-1894.
19. Trinchieri G. Recognition of major histocompatibility complex class I antigens by natural killer cells. J Exp Med 1994; 180:417-421.
20. Moretta A., Biassoni R., Bottino C., Pende D., Vitale M. et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997; 155:105-117.
21. Long E.O., Burshtyn D.N., Clark W.P., Peruzzi M., Rajagopalan S. et al. Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev 1997; 155:135-144.
22. Yewdell J.W., and Bennink J.R. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 1992; 52:1-123.
23. Germain R.N., and Margulies D.H. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993; 11:403-450.
24. Schurmans L.R., Diehl L., Den Boer A.T., Sutmuller R.P., Boonman Z.F. et al. Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis. J Immunol 2001; 167:5832-5837.
25. Tanaka K., Sonoda K., and Streilein J.W. Acute rejection of orthotopic corneal xenografts in mice depends on CD4(+) T cells and self-antigen-presenting cells. Invest Ophthalmol Vis Sci 2001; 42:2878-2884.
26. Tsunobuchi H., Nishimura H., Goshima F., Daikoku T., Suzuki H. et al. A protective role of interleukin-15 in a mouse model for systemic infection with herpes simplex virus. Virology 2000; 275:57-66.
27. Dunne J., Lynch S., O'Farrelly C., Todryk S., Hegarty J.E. et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001; 167:3129-3138.
28. Carson W.E., Ross M.E., Baiocchi R.A., Marien M.J., Boiani N. et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest 1995; 96:2578-2582.
29. Puzanov I.J., Bennett M., and Kumar V. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J Immunol 1996; 157:4282-4285.